Docetaxel Injection

Docetaxel is a paclitaxel anti-tumor drug that exerts its anti-tumor effect by interfering with the microtubule network necessary for cell mitosis and interphase cell function. Docetaxel can bind to free tubulin, promote tubulin assembly into stable microtubules, and inhibit its depolymerization, resulting in the production of microtubule bundles that have lost their normal functions and the fixation of microtubules, thereby inhibiting cell mitosis. The binding of docetaxel to microtubules does not change the number of protofilaments. This is different from most spindle toxic drugs currently used in clinical practice.

The main ingredient of this product is docetaxel. Its chemical name is {2aR-[2aalpha;,4beta;,4abeta;,6beta;,9alpha;(alpha;R*,beta;S*),11alpha;,12alpha;,12aalpha;,12balpha;]}-beta;-{[(1,1-dimethylethoxy)carbonyl]amino}-alpha;-hydroxyphenylpropionic acid [12b-acetyloxy-12-benzoyloxy-2a,3,4,4a,5,6,9,10,11,12,12a,12b-twelve hydrogen-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methylene-1H-cyclodecapentaen[3,4]benzo[1,2-b]oxetan-9-yl] ester. Molecular formula: C43H53NO14. Molecular weight: 807.88.

This product is a light orange-yellow to orange-yellow clear liquid.

1. It is suitable for the treatment of locally advanced or metastatic breast cancer. 2. It is suitable for the treatment of locally advanced or metastatic non-small cell lung cancer, even after the failure of cisplatin-based chemotherapy.

Docetaxel can only be used for intravenous infusion. All patients must take oral glucocorticoids, such as dexamethasone, before receiving docetaxel treatment. Take it one day before docetaxel infusion, 16 mg per day, for at least 3 days to prevent allergic reactions and fluid retention. The recommended dose of docetaxel is 70-75 mg/m2, intravenous infusion for one hour, once every three weeks. According to the calculated amount of medication for the patient, draw the required dose with a syringe, dilute it into 5% glucose injection or 0.9% sodium chloride injection, shake gently, mix evenly, and the final concentration shall not exceed 0.74 mg/ml

1. Bone marrow suppression: Neutropenia is the most common adverse reaction and is usually severe (less than 500/mm3). It is reversible and does not accumulate. According to literature reports, fever and infection associated with neutropenia have occurred. Anemia is seen in most cases, and severe thrombocytopenia occurs in a few cases. 2. Allergic reactions: Severe allergic reactions may occur in some cases, characterized by hypotension and bronchospasm, requiring interruption of treatment. The patient can return to normal after stopping the infusion and immediate treatment. Mild allergic reactions may also occur in some cases. Such as flushing, erythema with or without itching, chest tightness, back pain, difficulty breathing, drug fever or chills. 3. Skin reactions often manifest as erythema, mainly seen on the hands and feet, and may also occur in local rashes on the arms, face and chest, sometimes accompanied by

1. Patients with a history of severe allergy to docetaxel or Tween-80; 2. Patients with a white blood cell count less than 1500/mm3; 3. Patients with severe liver damage.

Precautions for children: The effectiveness and safety of docetaxel in children have not been determined. Precautions for pregnancy and lactation: There is currently no adequate and strictly controlled clinical research data for pregnant women. If the patient uses this product during pregnancy, or becomes pregnant while using this product, she should be informed of the potential harm to the fetus and the potential risk of miscarriage. Women of childbearing potential should avoid pregnancy during treatment with this product. It is not clear whether docetaxel is excreted from human milk. Given that many drugs can be excreted in human milk and docetaxel may cause serious adverse reactions in breastfeeding infants, mothers should stop breastfeeding before using this product. Precautions for the elderly: Not yet clear.

In vitro studies have shown that CYP3A4 inhibitors may interfere with the metabolism of this product, so extreme caution should be exercised when it is used simultaneously with such drugs (such as ketoazole, erythromycin, cyclosporine, etc.).

Store at 2-8℃ in a sealed and dark place.

0.5 ml: 20 mg

18 months

Beijing Eastern Union Biopharmaceuticals, Ltd.

• Founded in:

  2001-01-17

• Address:

  No. 17, Zhonghe Street, Beijing Economic and Technological Development Zone, Beijing

• Tax NO.:

  911103028011490830

• Registered Funds:

  $9.8 million

• Email:

  Log in to view